Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Loss of heterozygosity and point mutation at Aprt locus in T cells and fibroblasts of Pms2−/− mice

Abstract

Mice null for the Pms2 mismatch repair (MMR) gene exhibit a predisposition to lymphoma, microsatellite repeat instability, and failure of spermatogenesis. To study the role of Pms2 in the maintenance of in vivo genomic integrity in somatic cells, we characterized Aprt mutations in T cells and fibroblasts of 129×C3H Pms2−/−Aprt+/− mice. The spontaneous frequency of DAP-resistant T lymphocytes, as a consequence of APRT-deficiency, was increased threefold. Point mutation, which accounted for less than 20% of the DAPr mutant clones in Pms2+/+ mice, was predominant in the mutant T cell clones from Pms2−/− mice. These point mutations were predominantly TA to CG transitions. Fibroblasts of Pms2−/− mice exhibited only a modest increase in the frequency of clones with point mutations, such that mitotic recombination was still the primary cause of APRT deficiency. Thus, the mutator phenotype as a consequence of PMS2 deficiency is tissue-dependent, which may be related to the tissue-specific tumor proneness of Pms2−/− mice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Andrew SE, Reitmair AH, Fox J, Hsiao L, Francis A, McKinnon M, Mak TW, Jirik FR . 1997 Oncogene 15: 123–129

  • Andrew SE, Xu XS, Baross-Francis A, Narayanan L, Milhausen K, Liskay RM, Jirik FR, Glazer PM . 2000 Carcinogenesis 21: 1291–1295

  • Baker SM, Bronner CE, Zhang L, Plug A W, Robatzek M, Warren G, Elliott EA, Yu J, Ashley T, Arnheim N, Flavell RA, Liskay RM . 1995 Cell 82: 309–319

  • Baross-Francis A, Makhani N, Liskay RM, Jirik FR . 2001 Oncogene 20: 619–625

  • Bielas JH, Heddle JA . 2000 Proc. Natl. Acad. Sci. USA 97: 11391–11396

  • Buermeyer AB, Deschenes SM, Baker SM, Liskay RM . 1999 Annu. Rev. Genet. 33: 533–564

  • Dush MK, Sikela JM, Khan SA, Tischfield JA, Stambrook PJ . 1985 Proc. Natl. Acad. Sci. USA 82: 2731–2735

  • Engle SJ, Stockelman MG, Chen J, Boivin G, Yum MN, Davies PM, Ying MY, Sahota A, Simmonds HA, Stambrook PJ, Tischfield JA . 1996 Proc. Natl. Acad. Sci. USA 93: 5307–5312

  • Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M, Wang JY . 1999 Nature 399: 806–809

  • Harfe BD, Jinks-Robertson S . 2000 Annu. Rev. Genet. 34: 359–399

  • Kolodner RD, Marsischky GT . 1999 Curr. Opin. Genet. Dev. 9: 89–96

  • Melton DW, Konecki DS, Brennand J, Caskey CT . 1984 Proc. Natl. Acad. Sci. USA 81: 2147–2151

  • Meng Q, Skopek TR, Walker DM, Hurley-Leslie S, Chen T, Zimmer DM, Walker VE . 1998 Environ. Mol. Mutagen. 32: 236–243

  • Mirsalis JC, Monforte JA, Wineger RA . 1995 Annu. Rev. Pharmacol. Toxicol. 35: 145–164

  • Modrich P, Lahue R . 1996 Annu. Rev. Biochem. 65: 101–133

  • Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM . 1997 Proc. Natl. Acad. Sci. USA 94: 3122–3127

  • Prolla TA, Baker SM, Harris AC, Tsao JL, Yao X, Bronner CE, Zheng B, Gordon M, Reneker J, Arnheim N, Shibata D, Bradley A, Liskay RM . 1998 Nat. Genet. 18: 276–279

  • Rose JA, Yates PA, Simpson J, Tischfield JA, Stambrook PJ, Turker MS . 2000 Cancer Res. 60: 3404–3408

  • Shaddock JG, Dobrovolsky VN, Mittelstaedt RA, Bendre S, Heflich RH, Parsons BL . 2001 Environ. Mol. Mutagen. 37: 68–

  • Shao C, Deng L, Henegariu O, Liang L, Raikwar N, Sahota A, Stambrook PJ, Tischfield JA . 1999 Proc. Natl. Acad. Sci. USA 96: 9230–9235

  • Shao C, Deng L, Henegariu O, Liang L, Stambrook PJ, Tischfield JA . 2000 Proc. Natl. Acad. Sci. USA 97: 7405–7410

  • Shao C, Stambrook PJ, Tischfield JA . 2001 Nat. Genet. 28: 169–172

  • Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP, Clarke AR . 1999 Proc. Natl. Acad. Sci. USA 96: 3911–3915

  • Yao X, Buermeyer AB, Narayanan L, Tran D, Baker SM, Prolla TA, Glazer PM, Liskay RM, Arnheim N . 1999 Proc. Natl. Acad. Sci. USA 96: 6850–6855

  • Zeng M, Narayanan L, Xu XS, Prolla TA, Liskay RM, Glazer PM . 2000 Cancer Res. 60: 4889–4893

  • Zhang H, Richards B, Wilson T, Lloyd M, Cranston A, Thorburn A, Fishel R, Meuth M . 1999 Cancer Res. 59: 3021–3027

Download references

Acknowledgements

We thank RM Liskay for generously providing us with Pms2 knockout mice. This work was supported by grants from NIH (R01DK38185, P01ES05652 and P30ES05022).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jay A Tischfield.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shao, C., Yin, M., Deng, L. et al. Loss of heterozygosity and point mutation at Aprt locus in T cells and fibroblasts of Pms2−/− mice. Oncogene 21, 2840–2845 (2002). https://doi.org/10.1038/sj.onc.1205358

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205358

Keywords

This article is cited by

Search

Quick links